心房颤动、抗血栓治疗与认知老化:一项基于人群的研究
这项基于人群的队列研究纳入2685名来自瑞典孔斯霍尔门老龄化与照护国家研究队列的无痴呆参与者,随访9年。心房颤动与更快的整体认知下降及痴呆风险增加相关,抗凝药使用可能与痴呆风险降低相关。
要点
- 心房颤动与更快的简易精神状态检查年下降及全因痴呆风险增加相关。
- 心房颤动与血管性和混合性痴呆风险增加相关,与阿尔茨海默病无显著关联。
- 在心房颤动患者中,使用抗凝药而非抗血小板药与痴呆风险降低60%相关。
核心结论
- 心房颤动与老年人更快的整体认知下降和痴呆风险增加相关。
- 抗凝药使用可能降低心房颤动患者的痴呆风险。
研究设计与样本
- 基于人群的队列研究,纳入2685名来自瑞典孔斯霍尔门老龄化与照护国家研究的无痴呆参与者,2001-2004年至2010-2013年定期检查。
- 心房颤动通过临床检查、心电图和患者登记确定。
- 采用简易精神状态检查评估整体认知功能,采用DSM-IV标准诊断痴呆,NINDS-AIREN标准诊断血管性痴呆,NINCDS-ADRDA标准诊断阿尔茨海默病。
- 数据分析使用多元线性混合效应模型和Cox回归模型。
主要发现
- 基线时识别出243名(9.1%)心房颤动参与者;9年随访期间,279名(11.4%)发生心房颤动,399名(14.9%)发生痴呆。
- 作为时变变量,心房颤动与更快的简易精神状态检查年下降显著相关(β系数=-0.24,95%CI:-0.31至-0.16)。
- 心房颤动与全因痴呆风险增加相关(HR=1.40,95%CI:1.11-1.77)。
- 心房颤动与血管性和混合性痴呆风险增加相关(HR=1.88,95%CI:1.09-3.23),但与阿尔茨海默病无显著关联(HR=1.33,95%CI:0.92-1.94)。
- 在现患或新发心房颤动患者中,使用抗凝药而非抗血小板治疗与痴呆风险降低60%相关(HR=0.40,95%CI:0.18-0.92)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the association of atrial fibrillation (AF) with cognitive decline and dementia in old age, and to explore the cognitive benefit of antithrombotic treatment in patients with AF. METHODS: This population-based cohort study included 2,685 dementia-free participants from the Swedish National Study on Aging and Care in Kungsholmen, who were regularly examined from 2001-2004 to 2010-2013. AF was ascertained from clinical examination, ECG, and patient registry. Global cognitive function was assessed using the Mini-Mental State Examination. We followed the DSM-IV criteria for the diagnosis of dementia, the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences) criteria for vascular dementia, and the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria for Alzheimer disease. Data were analyzed using multiple linear mixed-effects and Cox regression models. RESULTS: We identified 243 participants (9.1%) with AF at baseline. During the 9-year follow-up period, 279 participants (11.4%) developed AF and 399 (14.9%) developed dementia. As a time-varying variable, AF was significantly associated with a faster annual Mini-Mental State Examination decline (β coefficient = -0.24, 95% confidence interval [CI]: -0.31 to -0.16) and an increased hazard ratio (HR) of all-cause dementia (HR = 1.40, 95% CI: 1.11-1.77) and vascular and mixed dementia (HR = 1.88, 95% CI: 1.09-3.23), but not Alzheimer disease (HR = 1.33, 95% CI: 0.92-1.94). Among people with either prevalent or incident AF, use of anticoagulant drugs, but not antiplatelet treatment, was associated with a 60% decreased risk of dementia (HR = 0.40, 95% CI: 0.18-0.92). CONCLUSION: AF is associated with a faster global cognitive decline and an increased risk of dementia in older people. Use of anticoagulant drugs may reduce dementia risk in patients with AF.
引用
- Ding M, Fratiglioni L, Johnell K, et al. Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study. Neurology. 2018. PMID: 30305443. doi:10.1212/WNL.0000000000006456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。